乳腺癌组织miR-33a N-cadherin mRNA表达及其与患者术后5年预后关系研究

doi:10.3969/j.issn.1006-6233.2025.04.017

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1349 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the expression of microRNA-33a (miR-33a) and N-cadherin mRNA in breast cancer tissues and their relationship with the prognosis of patients within 5 years after surgery. Methods: The breast cancer tissues and adjacent normal tissues of 132 patients with breast cancer who received surgical treatment in the First People's Hospital of Longnan City from April 2017 to August 2019 were obtained.The miR-33a and N-cadherin mRNA expression of tissues was detected by Real-time fluorescence quantitative PCR.After 5 years of follow-up,patients were divided into good prognosis group (survival within 5 years,101 cases) and poor prognosis group (death within 5 years,31 cases).The expression levels of miR-33a and N-cadherin mRNA in cancerous and adjacent normal tissues were compared.The relationship and correlation between the expression of miR-33a and N-cadherin mRNA in breast cancer tissues and clinical pathological characteristics of patients were analyzed.The relationship between miR-33a and N-cadherin mRNA expression of breast cancer tissues and the 5-year survival rate after surgery was analyzed.The clinical pathological characteristics and the miR-33a and N-cadherin mRNA expression levels in good and poor prognosis groups were compared.The factors affecting the poor prognosis of breast cancer patients at 5 years after surgery were analyzed by Cox regression analysis.The ROC curve was plotted to analyze the predictive value of miR-33a and N-cadherin mRNA in breast cancer tissues for poor prognosis of patients within 5 years after surgery. Results: Compared with adjacent normal tissues,the expression level of miR-33a in breast cancer tissues was decreased (0.49±0.08 vs 1.00±0.04),and the expression level of N-cadherin mRNA was increased (4.52±0.71 vs 1.00±0.05) (t=65.511,56.819,all P<0.001).Patients with low expression of miR-33a and high expression of N-cadherin mRNA had a higher proportion of tumor diameter ≥2cm,TNM stage Ⅲ,low tumor differentiation,and lymph node metastasis than those with high expression of miR-33a and low expression of N-cadherin mRNA (all P<0.05).The expression of miR-33a in breast cancer tissues was negatively correlated with N-cadherin mRNA,tumor diameter,TNM stage,lymph node metastasis,and positively correlated with the degree of tumor differentiation (all P<0.05).N-cadherin mRNA was positively correlated with tumor diameter,TNM stage,lymph node metastasis,and negatively correlated with degree of tumor differentiation (all P<0.05).The 5-year overall survival rate of patients with high expression of miR-33a and low expression of N-cadherin mRNA (88.06%,88.41%) was higher than that of patients with low expression of miR-33a and high expression of N-cadherin mRNA (64.62%,63.49%),respectively (all P<0.05).Compared with the good prognosis group,the poor prognosis group had a higher proportion of patients with tumor diameter ≥2cm,TNM stage Ⅲ,low tumor differentiation,lymph node metastasis,higher expression level of N-cadherin mRNA,and lower expression level of miR-33a (all P<0.05).Tumor diameter ≥2cm,TNM stage Ⅲ,low tumor differentiation,lymph node metastasis,low expression of miR-33a and high expression of N-cadherin mRNA are independent risk factors affecting the poor prognosis of breast cancer patients within 5 years after surgery (all P<0.05).Compared with the AUC (0.841,0.860) predicted by miR-33a or N-cadherin mRNA alone,the AUC (0.939) of the combination of the two in predicting the poor prognosis of breast cancer patients at 5 years after surgery was higher (all P<0.05). Conclusion: The expression of miR-33a in breast cancer tissues is low,and the expression of N-cadherin mRNA is high,both of which are related to the clinical pathological characteristics and prognosis of patients within 5 years after surgery,and have a high predictive value for the poor prognosis of breast cancer patients within 5 years after surgery.

Key words： Breast cancer MiR-33a N-cadherin Clinical pathological characteristics Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.04.017 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I4/629

[1] Hyams DM,Bareket-Samish A,Rocha JEB,et al.Selecting postoperative adjuvant systemic therapy for early-stage breast cancer:an updated assessment and systematic review of leading commercially available gene expression assays[J].Surg Oncol,2024,130(2):166-187.
[2] Zeng W,Zou G,Cao X,et al.MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2[J].Cancer Cell Int,2020,20(1):85-96.
[3] Jiang Q,Li Y,Cai S,et al.GLUL stabilizes N-cadherin by antagonizing β-catenin to inhibit the progresses of gastric cancer[J].Acta Pharm Sin B,2024,14(2):698-711.
[4] Luo D,Zeng X,Zhang S,et al.Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway[J].Cell Mol Med,2023,27(3):456-469.
[5] Iwase T,Saji S,Iijima K,et al.Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor-positive breast cancer:AERAS,a randomized multicenter open-label phase Ⅲ trial[J].Clin Oncol,2023,41(18):3329-3338.
[6] Liu W,Cheng J.LINC00974 sponges miR-33a to facilitate cell proliferation,invasion,and EMT of ovarian cancer through HMGB2 upregulation[J].Genet Mol Biol,2022,45(1):20210224.
[7] Antoniali G,Dalla E,Mangiapane G,et al.APE1 controls DICER1 expression in NSCLC through miR-33a and miR-130b[J].Cell Mol Life Sci,2022,79(8):446-467.
[8] Rencuzogullari O,Yerlikaya PO,Gurkan AC,et al.Palbociclib negatively regulates fatty acid synthesis due to upregulation of AMPKα and miR-33a levels to increase apoptosis in Panc-1 and MiaPaCa-2 cells[J].Biotechnol Appl Biochem,2022,69(1):342-354.
[9] Rusak A,Gasior-Gtogowska M,Sargenti A,et al.Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma[J].Pharmacol Rep,2025,77(1):210-228.
[10] Chen K,Yuan X,Wang S,et al.MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage[J].Oncogene,2023,42(18):1438-1452.
[11] Wang L,Li S,Luo H,et al.PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages[J].Exp Clin Cancer Res,2022,41(1):303-323.
[12] Kucuk U,Ekmekci S,Talu CK,et al.Relationship of E-cadherin,beta-catenin,N-cadherin,ZEB1 and αSMA as epithelial mesenchymal transition markers with prognostic factors in early and advanced stage laryngeal squamous cell carcinomas[J].Indian Pathol Microbiol,2023,66(2):237-245.